Evidence map›Paper›PMID 42583118›Full record

ArticleESMO gastrointestinal oncology2026

Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.

M Malla, A Esmail, A Tin, M M Khayat, L Bathla, C Bridges, C M Brewer, J Ferguson, J B Ortiz, J Ensor and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

M MallaUniversity of Alabama at Birmingham, Birmingham, USA.
A EsmailHouston Methodist Neal Cancer Center, Houston, USA.
A TinNatera, Inc., Austin, USA.
M M KhayatNatera, Inc., Austin, USA.
L BathlaTexas Oncology, San Antonio, USA.
C BridgesNatera, Inc., Austin, USA.
C M BrewerNatera, Inc., Austin, USA.
J FergusonNatera, Inc., Austin, USA.
J B OrtizNatera, Inc., Austin, USA.
J EnsorNatera, Inc., Austin, USA.
K MageeNatera, Inc., Austin, USA.
J YuH. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
A R HeGeorgetown University Medical Center, Washington, DC, USA.
T CannonInova Schar Cancer Institute, Fairfax, USA.
A WinerInova Schar Cancer Institute, Fairfax, USA.
G G KingFred Hutchinson Cancer Center, Seattle, USA.
A MahipalSeidman Cancer Center, Case Western Reserve University, Cleveland, USA.
A NagarajanCleveland Clinic Florida, Weston, USA.
J W FransesUniversity of Chicago, Chicago, USA.
A FungtammasanNatera, Inc., Austin, USA.
A JurdiNatera, Inc., Austin, USA.
M C LiuNatera, Inc., Austin, USA.
S KodaliHouston Methodist Neal Cancer Center, Houston, USA.
A A ConnorHouston Methodist Neal Cancer Center, Houston, USA.
R M GhobrialHouston Methodist Neal Cancer Center, Houston, USA.
R D KimH. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
M AbdelrahimHouston Methodist Neal Cancer Center, Houston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Growing evidence supports the prognostic and predictive value of circulating tumor DNA (ctDNA) in gastrointestinal cancers. This study evaluated ctDNA as a prognostic biomarker for detecting molecular residual disease (MRD) and recurrence in patients with resected biliary tract cancer (BTC). Materials and methods: We retrospectively analyzed real-world data from patients ( Results: The median follow-up was 21 months (range 2-97). ctDNA detection rates during MRD and postdefinitive treatment surveillance windows were 23% (19 of 82) and 38% (31 of 82), respectively. ctDNA positivity during MRD and postdefinitive treatment surveillance was significantly associated with inferior relapse-free survival (RFS) and overall survival (OS). ctDNA positivity was the most significant prognostic factor associated with RFS during the MRD window [hazard ratio (HR) 15.86, 95% CI 4.69-53.6, Conclusions: Patients with ctDNA positivity during the MRD and postdefinitive treatment surveillance windows demonstrated significantly inferior RFS and OS, and ctDNA was more accurate than current clinical biomarkers. These findings highlight the value of ctDNA monitoring in improving prognostication in BTC, with the potential to enhance post-operative risk stratification and inform surveillance strategies through earlier detection of recurrence.

Indexed as

biliary tract cancersbiomarkersmolecular residual diseaserecurrence monitoring

Identifiers

PMID42583118
PMCPMC13459594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.